A CFTR corrector (lumacaftor) and a CFTR potentiator (ivacaftor) for treatment of patients with cystic fibrosis who have a phe508del CFTR mutation: a phase 2 randomised controlled trial.
about
Update in Cystic Fibrosis 2014Potentiators (specific therapies for class III and IV mutations) for cystic fibrosisNew and emerging targeted therapies for cystic fibrosisManipulating proteostasis to repair the F508del-CFTR defect in cystic fibrosisAdvancing clinical development pathways for new CFTR modulators in cystic fibrosisTargeted therapies to improve CFTR function in cystic fibrosisCystic fibrosis transmembrane conductance regulator modulators in cystic fibrosis: current perspectivesCFTR Modulators: Shedding Light on Precision Medicine for Cystic FibrosisCurrent and Emerging Therapies for the Treatment of Cystic Fibrosis or Mitigation of Its SymptomsPrecision Genomic Medicine in Cystic FibrosisPseudomonas aeruginosa Reduces VX-809 Stimulated F508del-CFTR Chloride Secretion by Airway Epithelial CellsMechanistic Approaches to Improve Correction of the Most Common Disease-Causing Mutation in Cystic FibrosisIncreasing the Endoplasmic Reticulum Pool of the F508del Allele of the Cystic Fibrosis Transmembrane Conductance Regulator Leads to Greater Folding Correction by Small Molecule TherapeuticsPaediatrics: messages from MunichIn vivo and in vitro ivacaftor response in cystic fibrosis patients with residual CFTR function: N-of-1 studies.Phenotypic profiling of CFTR modulators in patient-derived respiratory epithelia.Lumacaftor/ivacaftor combination for cystic fibrosis patients homozygous for Phe508del-CFTR.Structure-activity analysis of a CFTR channel potentiator: Distinct molecular parts underlie dual gating effects.Repeated nebulisation of non-viral CFTR gene therapy in patients with cystic fibrosis: a randomised, double-blind, placebo-controlled, phase 2b trial.Lumacaftor and ivacaftor in the management of patients with cystic fibrosis: current evidence and future prospects.PharmGKB summary: very important pharmacogene information for CFTRF508del-cystic fibrosis transmembrane regulator correctors for treatment of cystic fibrosis: a patent review.Recent advances in understanding and managing cystic fibrosis transmembrane conductance regulator dysfunction.Inhibiting an Epoxide Hydrolase Virulence Factor from Pseudomonas aeruginosa Protects CFTR.Rhinovirus Load Is High despite Preserved Interferon-β Response in Cystic Fibrosis Bronchial Epithelial Cells.Tackling the increasing complexity of CF care.Electronic monitoring reveals highly variable adherence patterns in patients prescribed ivacaftor.Potentiators of Defective ΔF508-CFTR Gating that Do Not Interfere with Corrector Action.The Enigmatic Gut in Cystic Fibrosis: Linking Inflammation, Dysbiosis, and the Increased Risk of Malignancy.From CFTR biology toward combinatorial pharmacotherapy: expanded classification of cystic fibrosis mutations.Lumacaftor-Ivacaftor in Patients with Cystic Fibrosis Homozygous for Phe508del CFTR.Combination therapy with cystic fibrosis transmembrane conductance regulator modulators augment the airway functional microanatomy.Cystic fibrosis: a model system for precision medicine.A novel treatment of cystic fibrosis acting on-target: cysteamine plus epigallocatechin gallate for the autophagy-dependent rescue of class II-mutated CFTRDevelopment of Automated Patch Clamp Technique to Investigate CFTR Chloride Channel Function.Cysteamine re-establishes the clearance of Pseudomonas aeruginosa by macrophages bearing the cystic fibrosis-relevant F508del-CFTR mutation.Cystic fibrosis genetics: from molecular understanding to clinical application.Aspects of pulmonary drug delivery strategies for infections in cystic fibrosis--where do we stand?Pharmacogenetic Markers of Drug Efficacy and Toxicity.Changing the Paradigm - Treating the Basic Defect in Cystic Fibrosis.
P2860
Q22306307-E255A851-94C7-43FF-9595-19304998D4B1Q24187139-D2847A9C-BE90-4803-BE78-84B1142B614CQ26749278-26378CA2-1D26-48D0-8A38-C194D402E432Q26765794-16FCA513-3594-4BAC-BD36-0327592D913DQ26768266-6C6873E6-1451-47A9-86C9-263264F3B7DBQ26781441-6862F88D-555E-4F72-8BB6-B2114DA82572Q28073063-3F6C5CDF-B763-4B4B-B7F3-6032B0208E10Q28073996-3FB9B507-4B6D-414B-A6FD-7BEC2B18B811Q28077411-8F0153B6-0FE6-4432-BE0B-E6FE6742B9D3Q28080906-3EE97E2D-B1FE-4518-928B-AC9D7AB3EF96Q28547516-D43B2EC9-F934-4FD2-ABC4-1598F6C6D03CQ28552337-E8F6655F-34EA-461A-BBC9-31CFABDA3CB2Q28554668-CBB51844-CAF3-4B40-9F03-A048935830D1Q28596759-97E64F83-8843-4FEB-9C9C-453790C2ED2FQ33769791-6C0C3977-9F27-4FCC-B01D-684EB4B26BBBQ33825789-395898D3-4727-442F-80DA-E79D0119EC9AQ33865292-4EC0D703-730A-43D8-85EF-CFEB5850CBB5Q34262476-3BE568A2-CA7B-4CF5-B5C3-3D6970DE10B2Q34483772-45B7ABFC-4BC7-4A69-9BC7-8D37E8A225C4Q34496122-ED29692A-7705-4ECC-ACA7-6D90385EC886Q35108743-3382D90C-6A11-450C-8466-D780DF8929CDQ35630919-84ADFF07-BC92-41F8-AFB5-D42AEA189327Q35659323-51DB37AC-AB36-4A2A-AAA5-2702C3359185Q35681388-413A1C6D-33F1-410B-AC0D-284843E93C19Q35849673-C389AF20-68F2-4BC7-A509-006D8BCAFEDBQ36034488-F4E8E15C-1E90-4AA5-8857-534580AEAFD8Q36054346-C146D566-BAF3-404D-B854-FBD4557FB508Q36077743-94E5C1B2-9E0D-4C6D-AD03-4A97DA61D635Q36268539-8628B185-C106-4636-98C4-AE4CDBDF5785Q36574664-4C67F0AE-C78A-48BD-A54D-738352A3C5F0Q36609344-B894100B-49B8-4256-AFFF-944F66A24C1AQ36976621-5DC02B73-4E8B-4247-A508-BADFB9B48133Q37097931-2B277D5A-EAA0-4575-9FC5-F35E4D22CCBFQ37100647-4A592201-D0DE-4FBA-93A3-31E692911986Q37740542-06E98043-09B3-41B3-BFCE-A69E49E40E96Q37744944-732B2730-5123-4650-9935-382EBA9C113CQ38268916-B43B6D4B-9DDF-4F03-BD5C-634BB9568136Q38340865-BA4B8B68-1960-41F9-B876-E655408B045BQ38419534-52E643A4-4618-405E-9A86-4DF3859C9675Q38528320-E9E5B673-AB95-4F9A-A253-0F227EBE3B4D
P2860
A CFTR corrector (lumacaftor) and a CFTR potentiator (ivacaftor) for treatment of patients with cystic fibrosis who have a phe508del CFTR mutation: a phase 2 randomised controlled trial.
description
2014 nî lūn-bûn
@nan
2014 թուականի Յունիսին հրատարակուած գիտական յօդուած
@hyw
2014 թվականի հունիսին հրատարակված գիտական հոդված
@hy
2014年の論文
@ja
2014年論文
@yue
2014年論文
@zh-hant
2014年論文
@zh-hk
2014年論文
@zh-mo
2014年論文
@zh-tw
2014年论文
@wuu
name
A CFTR corrector (lumacaftor) ...... 2 randomised controlled trial.
@ast
A CFTR corrector (lumacaftor) ...... 2 randomised controlled trial.
@en
A CFTR corrector
@nl
type
label
A CFTR corrector (lumacaftor) ...... 2 randomised controlled trial.
@ast
A CFTR corrector (lumacaftor) ...... 2 randomised controlled trial.
@en
A CFTR corrector
@nl
prefLabel
A CFTR corrector (lumacaftor) ...... 2 randomised controlled trial.
@ast
A CFTR corrector (lumacaftor) ...... 2 randomised controlled trial.
@en
A CFTR corrector
@nl
P2093
P921
P1476
A CFTR corrector (lumacaftor) ...... 2 randomised controlled trial.
@en
P2093
David Rodman
David Waltz
Ernst Rietschel
Michael P Boyle
Michael W Konstan
Naimish R Patel
Scott C Bell
Steven M Rowe
Susanna A McColley
VX09-809-102 study group
P304
P356
10.1016/S2213-2600(14)70132-8
P577
2014-06-24T00:00:00Z